Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Packer

Showing results (681-690 of 706) with videos related to

Pageof 71
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2013
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1Lori A Ramkissoon, Peleg M Horowitz, Justin M Craig, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Journal of Medicinal Chemistry|December 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective InhibitorJeffrey W Johannes, Amber Y S Balazs, Derek Barratt, et al.
Nature Human Behaviour|May 2, 2020
Using social and behavioural science to support COVID-19 pandemic responseJay J Van Bavel, Katherine Baicker, Paulo S Boggio, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
The Lancet. Oncology|October 22, 2013
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
The Lancet. Respiratory Medicine|December 16, 2018
Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association studyNick Shrine, Michael A Portelli, Catherine John, et al.
Neuro-Oncology|December 22, 2025
Molecular and Clinical Stratification of Astroblastomas: Three distinct Fusion-Defined Groups Informing Risk-Adapted Treatment StrategiesAniello Federico, Felix Schmitt-Hoffner, Adriana Fonseca, et al.
Pageof 71

Showing results (681-690 of 706) with videos related to

Sort By:
Pageof 71
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2013
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1Lori A Ramkissoon, Peleg M Horowitz, Justin M Craig, et al.
Neuro-Oncology|October 23, 2024
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directionsMary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Journal of Medicinal Chemistry|December 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective InhibitorJeffrey W Johannes, Amber Y S Balazs, Derek Barratt, et al.
Nature Human Behaviour|May 2, 2020
Using social and behavioural science to support COVID-19 pandemic responseJay J Van Bavel, Katherine Baicker, Paulo S Boggio, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
The Lancet. Oncology|October 22, 2013
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
The Lancet. Respiratory Medicine|December 16, 2018
Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association studyNick Shrine, Michael A Portelli, Catherine John, et al.
Neuro-Oncology|December 22, 2025
Molecular and Clinical Stratification of Astroblastomas: Three distinct Fusion-Defined Groups Informing Risk-Adapted Treatment StrategiesAniello Federico, Felix Schmitt-Hoffner, Adriana Fonseca, et al.
Pageof 71